3-(4-fluorophenylamino)-3-oxo-2-phenylpropanoic acid | 1259521-33-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-fluorophenylamino)-3-oxo-2-phenylpropanoic acid
• 英文别名: 3-(4-fluoroanilino)-3-oxo-2-phenylpropanoic acid
• CAS: 1259521-33-9
• 化学式: C₁₅H₁₂FNO₃
• 分子量: 273.264
• InChiKey: WJJKGDGCUQSJRZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(4-fluorophenylamino)-3-oxo-2-phenylpropanoic acid 在 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex 、 potassium carbonate 、 三氯氧磷 作用下， 以 四氢呋喃 为溶剂， 反应 10.0h， 生成 4-chloro-2-ethyl-6-fluoro-3-phenylquinoline
  参考文献：
  名称：

  Synthesis and SAR study of potent and selective PI3Kδ inhibitors

  摘要：

  2,3,4-Substituted quinolines such as (10a) were found to be potent inhibitors of PI3K delta in both biochemical and cellular assays with good selectivity over three other class I PI3K isoforms. Some of those analogs showed favorable pharmacokinetic properties. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.01.001
• 作为产物：
  描述：

  苯基丙二酸二乙酯 在 吡啶 、 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 生成 3-(4-fluorophenylamino)-3-oxo-2-phenylpropanoic acid
  参考文献：
  名称：

  Synthesis and SAR study of potent and selective PI3Kδ inhibitors

  摘要：

  2,3,4-Substituted quinolines such as (10a) were found to be potent inhibitors of PI3K delta in both biochemical and cellular assays with good selectivity over three other class I PI3K isoforms. Some of those analogs showed favorable pharmacokinetic properties. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.01.001

文献信息

• HETEROCYCLIC COMPOUNDS AND THEIR USES
  申请人：Bui Minna

  公开号：US20100331306A1

  公开（公告）日：2010-12-30

  Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

  含有替代双环杂环芳基的化合物及其组合物，用于治疗一般性炎症、关节炎、风湿性疾病、骨关节炎、炎性肠道疾病、炎性眼部疾病、炎性或不稳定膀胱疾病、牛皮癣、具有炎症成分的皮肤疾病、慢性炎症症状，包括但不限于自身免疫疾病如系统性红斑狼疮（SLE）、重症肌无力、类风湿关节炎、急性播散性脑脊髓炎、特发性血小板减少性紫癜、多发性硬化、Sjogren综合症和自身免疫性溶血性贫血，包括各种过敏症状。本发明还提供了一种治疗与p110δ活性有关、依赖于或相关的癌症的方法，包括但不限于白血病，如急性髓细胞白血病（AML）、髓增生异常综合征（MDS）、髓增生性疾病（MPD）、慢性髓细胞白血病（CML）、T细胞急性淋巴细胞白血病（T-ALL）、B细胞急性淋巴细胞白血病（B-ALL）、非霍奇金淋巴瘤（NHL）、B细胞淋巴瘤和实体瘤，如乳腺癌。
• POLYCYCLIC DERIVATIVES OF PYRIDINE AND THEIR USE IN THE TREATMENT OF (INTER ALIA) RHEUMATOID ARTHRITIS AND SIMILAR DISEASES
  申请人：Amgen, Inc

  公开号：EP2445900A2

  公开（公告）日：2012-05-02
• US9873704B2
  申请人：——

  公开号：US9873704B2

  公开（公告）日：2018-01-23
• [EN] HETEROCYCLIC COMPOUNDS AND THEIR USES<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET UTILISATIONS CORRESPONDANTES
  申请人：AMGEN INC

  公开号：WO2010151740A2

  公开（公告）日：2010-12-29

  Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.
• Synthesis and SAR study of potent and selective PI3Kδ inhibitors
  作者：Minna Bui、Xiaolin Hao、Youngsook Shin、Mario Cardozo、Xiao He、Kirk Henne、Julia Suchomel、John McCarter、Lawrence R. McGee、Tisha San Miguel、Julio C. Medina、Deanna Mohn、Thuy Tran、Sharon Wannberg、Jamie Wong、Simon Wong、Leeanne Zalameda、Daniela Metz、Timothy D. Cushing

  DOI：10.1016/j.bmcl.2015.01.001

  日期：2015.3

  2,3,4-Substituted quinolines such as (10a) were found to be potent inhibitors of PI3K delta in both biochemical and cellular assays with good selectivity over three other class I PI3K isoforms. Some of those analogs showed favorable pharmacokinetic properties. (C) 2015 Elsevier Ltd. All rights reserved.